Hengrui：SHR4640 approved for marketing in China.
Northland：NL003 received marketing approval
JMT-Bio/Alphamab Oncology：Anbenitamab was approved
Fosun Pharma：AKYNZEO®fosnetupitant/palonosetron concentrated solution for injectionapproved for marketing in China.
Chia Tai Tianqing：Symproic®Naldemedinehas been formally accepted for review.
Renhe Yikang：Topamax Topiramate was approved for marketing and deemed to have passed the consistency evaluation.
Roche：Giredestrant receives FDA filing acceptance
Boundless Bio：Bepirovirsen was not approved by the NMPA recently.
Hengrui ：HRS-7535 for Phase III Clinical Trial in Chronic Kidney Disease
Roche：Gazyva® Obinutuzumab Granted Priority Review
